Extended Data Fig. 3: ILC2-dependent anti-tumor immunity in Il7r^Cre/+Rora^Δ/Δ mice.

a-e, Ret tumor growth and immune cell composition of Ly5.1^+/+ chimeric mice reconstituted with C57BL/6 J (CD45.2^+/+) or Il7r^Cre/+Rora^Δ/Δ (CD45.2^+/+)²⁸ bone marrow. a, Schematic representation of the experimental design. b, Ret tumor growth over time (left) and day 18 tumor size (right). Statistical analyses of tumor growth were performed using TumGrowth. Data represents one experiment with 6 mice/genotype and show the mean ± s.e.m. c-d, Representative flow cytometric contour plots (left panels) and enumeration (right panels) of intestinal (c) and tumor-infiltrating (d) ILC2 at day 13 after Ret tumor cell inoculation. ILC2 were defined as live CD45.2⁺lin^-(CD3ε^-TCRβ^-CD19^-CD11b^-NKp46^-RORγt^-) CD90.2⁺GATA3⁺ cells. e, Enumeration of tumor infiltrating leukocytes cells at day 13 post Ret tumor inoculation. Leukocytes were defined as live CD45⁺; B cells as live CD45⁺CD3ε^-TCRβ^-CD19⁺; CD4⁺ T cells as live CD45⁺CD3ε⁺TCRβ⁺CD4⁺; CD8⁺ T cells as live CD45⁺CD3ε⁺TCRβ⁺CD8⁺; NK cells as live CD45⁺CD3ε^-TCRβ^-CD19^-(lin^-)NKp46⁺Eomes⁺; ILC1 as live lin^-NKp46⁺Eomes^-; and ILC3 as live lin^-CD11b^-NKp46^-RORγt⁺. Data pooled from 2 independent experiments (n = 6 mice/genotype/experiment) and show the mean ± s.e.m. b-e. Each circle represents one mouse and p-values are indicated.